MEGGLE launches micronized inhaler lactose InhaLac® 500
Press Release | MEGGLE Excipients & Technology
MAY 10, 2017
Developed at MEGGLE’s Wasserburg laboratories in Germany, InhaLac® 500 is MEGGLE´s first micronized lactose grade, specifically designed for inhalation with extremely small particles. Combined with high quality and safety, this material meets the most demanding individual dry powder inhalation formulation requirements.
InhaLac® 500 is the finest grade of the InhaLac® product family which also includes sieved grades InhaLac® 70, InhaLac® 120, InhaLac® 230 and InhaLac® 251, along with milled grade InhaLac® 400.
High cohesion and stability
The micronization process used for InhaLac® 500 produces very small particles, high cohesive properties and even distribution, with 90 % of the particles being smaller than 10 μm (x50 ≤ 5 μm). This allows a wider choice of applications as fines or as co-agglomerate in dry powder inhalation products.
A further key benefit is long shelf life, with high stability and a retest date of 12 month.
InhaLac® 500 is a micronized ultra fine lactose that is suitable for ternary DPI formulations. The addition of micronized fines improves the drug product performance, particularly with regard to fine particle fractions (FPF) when used in ternary mixtures. This can be related to several known effects, such as buffer effect or the saturation of high-energy active sites. Further, the high cohesiveness of the micronized material helps to alter the fluidization behavior of the powder blend.
The micronized size with an x90 smaller than 10 µm, makes InhaLac® 500 ideally suited for application in soft spherical pellet formulations and across a range of different formulation types, for example as micronized fines in ternary adhesive mixtures (5-15 % wt.) or as filler in soft spherical pellets.
About MEGGLE Wasserburg
MEGGLE AG, with its headquarters in the Bavarian city of Wasserburg, serves as a holding company for various business activities in the dairy industry and whey processing. MEGGLE has a proud history of more than 125 years in the dairy market.
The MEGGLE Excipients & Technology business group produces pharmaceutical excipients for direct compression, granulation, capsules, sachets, powder blends and dry powder inhalers. With its broad product portfolio, intelligent innovations and exceptional product quality, MEGGLE has assumed a leading role in the global business of pharmaceutical excipients as an acknowledged world expert in lactose and its applications in pharmaceuticals.
MEGGLE Excipients & Technology has harnessed outstanding product quality and intelligent innovation to become a global leader in the manufacture of lactose-based excipients, focusing on products for direct tableting and dry powder inhalation.
BG Excipients & Technology has introduced several pioneering products, notably Tablettose®, the world’s first agglomerated lactose for direct tableting, Cellactose® 80, a pioneering co-processed excipient based on cellulose-lactose for outstanding compression and flow properties and RetaLac®, the first co-processed excipient to use a hypromellose-lactose base for extended release formulations.
Dr. Mirjam Kobler, MEGGLE Excipients & Technology
Tel: +49 8071 73 138
Ruth Leinenbach, Director MEGGLE BG Excipients & Technology
Tel: +49 8071 73 495